Should stage I non-small-cell lung cancer patients who are unsuitable for surgery receive hypofractionated stereotactic radiotherapy? How safe is this form of radiation treatment? Nature Clinical Practice Oncology
Erythropoiesis-stimulating agents should continue to have an oncology indication, even though questions about their safety remain. Medscape Medical News
In this Expert Interview, Lisa Carey, MD, discusses the biologic differences that underlie differences in breast tumor behavior and outcomes. Medscape Hematology-Oncology
Normal precursor B cells and lymphoblasts of precursor B-ALL may be hard to distinguish. How is an immunofluorescence test for TdT that can differentiate hematogones from leukemic blasts applied? American Journal of Clinical Pathology
In this Expert Interview from SABCS 2007, Dr. William J. Gradishar details the latest novel drug combinations that may benefit patients with advanced breast cancer. Medscape Hematology-Oncology
Carriers of the alpha1-antitrypsin deficiency might have a risk of developing lung cancer that is up to 70% higher than that for noncarriers of the genetic defect. Medscape Medical News